JANX (Janux Therapeutics) Short Interest


JANX Janux Therapeutics Inc JANX
46 GF Score
Price $14.81
GF Value $39.21
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Janux Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

JANX vs ANNX, XNCR, SPRY: Short Interest Comparison

For the Biotechnology subindustry, Janux Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Janux Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Janux Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Janux Therapeutics's Short Interest falls into.


JANX
46GF Score
Janux Therapeutics Inc JANX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Janux Therapeutics (JANX) Overvalued in 2026?

Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued. The current stock price of $14.81 is trading 62.2% below its estimated GF Value™ of $39.21. GuruFocus considers Janux Therapeutics to be Possible Value Trap.

Key valuation signals for JANX:

  • Short Interest:
  • GF Value™: $39.21 vs. price of $14.81 (62.2% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Janux Therapeutics Business Description

Address 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
46GF Score

Get the complete analysis for JANX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.81
Price
$39.21
GF Value